Schizophrenia News and Research

Latest Schizophrenia News and Research

Ligand Pharmaceuticals acquires Neurogen

Ligand Pharmaceuticals acquires Neurogen

Neurocrine to advance its NBI-98854 VMAT2 Inhibitor into a multiple repeated dose Phase 1 study

Neurocrine to advance its NBI-98854 VMAT2 Inhibitor into a multiple repeated dose Phase 1 study

Intra-Cellular Therapies announces results of its ITI-007 antipsychotic drug Phase I study

Intra-Cellular Therapies announces results of its ITI-007 antipsychotic drug Phase I study

Diet rich in omega-3 fatty acids linked to improved nervous-system function

Diet rich in omega-3 fatty acids linked to improved nervous-system function

Naurex' GLYX-13 demonstrates antidepressant-like and anxiolytic-like activity without CNS-related side effects

Naurex' GLYX-13 demonstrates antidepressant-like and anxiolytic-like activity without CNS-related side effects

Naurex commences dosing in its GLYX-13 Phase I clinical trial for treatment-resistant depression

Naurex commences dosing in its GLYX-13 Phase I clinical trial for treatment-resistant depression

Alexza Pharmaceuticals submits its NDA for Staccato loxapine to FDA

Alexza Pharmaceuticals submits its NDA for Staccato loxapine to FDA

ZYPREXA RELPREVV approved by FDA

ZYPREXA RELPREVV approved by FDA

New biosensors show how schizophrenia drugs alter brain chemistry

New biosensors show how schizophrenia drugs alter brain chemistry

Targacept commences TC-5619 Phase 2 study of cognitive dysfunction in schizophrenia

Targacept commences TC-5619 Phase 2 study of cognitive dysfunction in schizophrenia

Schizophrenia: Once-monthly INVEGA SUSTENNA not inferior to bi-weekly RISPERDAL CONSTA

Schizophrenia: Once-monthly INVEGA SUSTENNA not inferior to bi-weekly RISPERDAL CONSTA

Eli Lilly provides financial guidance for 2010

Eli Lilly provides financial guidance for 2010

CMHA calls to extend Employment Insurance benefits and Pharmacare program for mentally-ill patients

CMHA calls to extend Employment Insurance benefits and Pharmacare program for mentally-ill patients

ACNP 2009 to feature research on PTSD, biomarkers for schizophrenia and treatment for gambling addiction

ACNP 2009 to feature research on PTSD, biomarkers for schizophrenia and treatment for gambling addiction

NYSE Amex to delist Cortex Pharmaceuticals

NYSE Amex to delist Cortex Pharmaceuticals

Successful reduction in the levels of aggregated Abeta with GSMs

Successful reduction in the levels of aggregated Abeta with GSMs

Psychological trauma leaves a trail of damage in a child's brain, reveal scientists

Psychological trauma leaves a trail of damage in a child's brain, reveal scientists

Two Brown University faculty members receive federal funding for new neuroscience research projects

Two Brown University faculty members receive federal funding for new neuroscience research projects

Janssen-Cilag submits MAA to the European Medicines Agency for paliperidone palmitate

Janssen-Cilag submits MAA to the European Medicines Agency for paliperidone palmitate

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.